Obermatt
See Similar Stocks →

RxSight

NMQ:RXST · US78349D1072
Health Care Equipment & SuppliesSmall

360

20
EV / EBIT97
Price / Owner Earnings78
Owner Earnings Yield1
Dividend Yield1
Price/Sales76
Price/Book89
Return on Capital7
Cash Return on Capital17
Return on Equity20
EBIT Margin6
Gross Profitability54
Accruals87
Owner Earnings Margin14
Sales growth8
Profit Growth10
Long-Term EPS Growth95
Reinvestment78
Price momentum3
Debt load89
Refinancing83
Debt Payback1
Liquidity1
Analyst ratings3
Opinion Changes50
Price Target Upside98
Market mood57
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

RxSight doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded1997
Employees328
Websiterxsight.com
ISINUS78349D1072
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Biomedical EngineeringHealth DiagnosticsOphthalmologySurgeryBiotechnologyConsumer GoodsHealth CareScience and Engineering

Description

RxSight, Inc. operates as a commercial-stage medical technology company. The company is dedicated to providing customized vision to patients following cataract surgery. The company’s proprietary RxSight Light Adjustable Lens system (RxSight system)…

Analysis

Middle-of-the-road

RxSight, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
37
2023202420252026

All-time high

84

Jan 2025

All-time low

14

Mar 2026

Average rank

41

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
76
14
5
30
Price/Earnings
84
16
16
22
Price/Book
89
39
16
93
Dividend Yield
1
1
1
1
Value (overall)
89
23
6
57

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare RxSight with its peers
PROCEPT BioRobotics
NMQ:PRCT
19
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
Avanos Medical
NYQ:AVNS
48
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
TELA Bio
NMQ:TELA
19
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Staar Surgical
NMQ:STAA
39
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
Cooper
NSQ:COO
28
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeX-Large
Full Stock Analysis →
UFP Technologies
NAQ:UFPT
69
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →